Philips (PHG) has announced the launch of its interventional guidance platform, IntraSight Plus, which is cleared for clinical use in the USA and Europe. With CE marking and FDA 510 clearance, the redesigned platform combines diagnostic and treatment planning tools. By streamlining access to interventional tools, IntraSight Plus enables clinicians to diagnosis, virtually plan treatment, guide device placement and verify results all on a single screen.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHG:
- Philips removed from European Conviction List at Goldman Sachs
- Royal Philips Files 2025 Annual Report Highlighting Growth, Cash Generation and ESG Progress
- Philips price target raised to EUR 26 from EUR 25 at Morgan Stanley
- Philips introduces InkSpace Imaging’s Snuggle flexible pediatric MRI coil
- Philips price target raised to EUR 22.60 from EUR 19.60 at JPMorgan